BESCHWERDEKAMMERN PATENTAMTS

BOARDS OF APPEAL OF OFFICE

CHAMBRES DE RECOURS DES EUROPÄISCHEN THE EUROPEAN PATENT DE L'OFFICE EUROPÉEN DES BREVETS

Internal distribution code:

- (A) [] Publication in OJ
- (B) [] To Chairmen and Members
- (C) [] To Chairmen
- (D) [X] No distribution

Datasheet for the decision of 17 January 2020

Case Number: T 0548/16 - 3.3.01

Application Number: 06118876.9

Publication Number: 1731152

IPC: A61F13/00, A61K31/485,

A61K9/70, A61P25/04

Language of the proceedings: ΕN

Title of invention:

Sustained analgesia achieved with transdermal delivery of buprenorphine

Patent Proprietor:

EURO-CELTIQUE S.A. Mundipharma Laboratories GmbH Napp Pharmaceutical Holdings Limited Mundipharma Pharmaceuticals B.V. Mundipharma AB Mundipharma Pharmaceuticals Limited Norpharma A/S Mundipharma OY

Opponents:

Hexal AG Gallafent, Alison tesa Labtec GmbH

Headword:

Sustained analgesia with buprenorphine / EURO-CELTIQUE

Relevant legal provisions:

EPC Art. 113(2)

Keyword:

Basis of decision - text or agreement to text withdrawn by patent proprietor



Beschwerdekammern **Boards of Appeal** Chambres de recours

Boards of Appeal of the European Patent Office Richard-Reitzner-Allee 8 85540 Haar **GERMANY** Tel. +49 (0)89 2399-0 Fax +49 (0)89 2399-4465

Case Number: T 0548/16 - 3.3.01

DECISION of Technical Board of Appeal 3.3.01 of 17 January 2020

Appellant:

(Patent Proprietor 1)

EURO-CELTIQUE S.A. 1, rue Jean Piret 2350 Luxembourg (LU)

Appellant:

Mundipharma Laboratories GmbH St. Alban-Rheinweg 74

(Patent Proprietor 2)

4020 Basel (CH)

Appellant:

Napp Pharmaceutical Holdings Limited Cambridge Science Park

(Patent Proprietor 3)

Milton Road Cambridge CB4 OAB (GB)

Appellant:

Mundipharma Pharmaceuticals B.V.

De Wel 20 (Patent Proprietor 4)

3871 Hoevelaken (NL)

Appellant:

Mundipharma AB Mölndalsvägen 26 (Patent Proprietor 5) 412 63 Göteborg (SE)

Appellant:

Mundipharma Pharmaceuticals Limited

Millbank House (Patent Proprietor 6)

Arkle Road Sandyford Dublin 18 (IE) Appellant:

Norpharma A/S Frydenlundsvej 30 (Patent Proprietor 7) 2950 Vedbaek (DK)

Appellant:

Mundipharma OY Rajatorpantie 41 C (Patent Proprietor 8) 01640 Vantaa (FI)

Representative:

Hansen, Norbert

Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH

Elisenhof Elisenstraße 3 80335 München (DE)

Appellant:

Hexal AG

Industriestrasse 25 (Opponent 1)

83607 Holzkirchen (DE)

Representative:

Ter Meer Steinmeister & Partner

Patentanwälte mbB Nymphenburger Straße 4 80335 München (DE)

Appellant:

(Opponent 2)

Gallafent, Alison Alison Gallafent Ltd

21 Bridge St

Llandeilo SA19 6BN (GB)

Representative:

Bird & Bird LLP Maximiliansplatz 22 80333 München (DE)

Intervener: (Opponent 3) tesa Labtec GmbH Raiffeisenstrasse 4 40764 Langenfeld (DE)

Representative:

Bird & Bird LLP Maximiliansplatz 22 80333 München (DE)

Decision under appeal:

Interlocutory decision of the Opposition Division of the European Patent Office posted on 3 March 2016 concerning maintenance of the European Patent No. 1731152 in amended form.

Composition of the Board:

Chairman A. Lindner Members: S. Albrecht

Y. Podbielski

- 1 - T 0548/16

Summary of Facts and Submissions

- I. Appeals were lodged by opponents 01 and 02 as well as by the patent proprietors (hereinafter "appellants-patent proprietors") against the decision of the opposition division announced at the oral proceedings on 10 November 2015 concerning maintenance of European Patent No. 1 731 152 in amended form.
- II. In their letter dated 19 December 2019, the appellants-patent proprietors declared
 - (a) that they no longer approved the text in which the patent had been granted,
 - (b) that they would not be submitting an amended text, and
 - (c) that they withdrew all requests on file.
- III. The oral proceedings which had been arranged for 14 January 2020 were thereafter cancelled.

Reasons for the Decision

- 1. Pursuant to Article 113(2) EPC, the EPO shall examine, and decide upon, the European patent only in the text submitted to it, or agreed, by the proprietor of the patent.
- 2. Such an agreement cannot be deemed to exist where as in the present case the proprietor expressly states that it no longer approves the text of the patent as granted and withdraws all pending requests.

- 2 - T 0548/16

3. There is therefore no text of the patent on the basis of which the Board can consider the appeal. In these circumstances, the proceedings are to be terminated by a decision ordering revocation of the patent, without examination as to patentability (Case Law of the Boards of Appeal of the European Patent Office, 9th edition 2019, IV.D.2).

Order

For these reasons it is decided that:

- 1. The decision under appeal is set aside.
- 2. The patent is revoked.

The Registrar:

The Chairman:



M. Schalow

A. Lindner

Decision electronically authenticated